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Purpose/Objective: The irradiation of lymph node regions in 
the post-mastectomy setting has been a matter of 
uncertainty. EORTC trial tested the irradiation of the internal 
mammary chain (IMC) and medial supraclavicular nodal 
region (SNR) in node-positive medial/central tumours and 
detected a 1.6% benefit in survival and 3% benefit in DFS at 5 
years. The preliminary results of the MA.20 suggest that 
regional irradiation may reduce distant metastases. A meta-
analysis of randomized trials concluded that irradiation of the 
lymph node regions improves outcomes. 
Materials and Methods: The IAEA conducted a prospective 
randomized clinical trial to compare the local control, 
regional control, overall and disease-free survival of stage IIA 
– IIIA breast cancer patients randomly assigned to post-
mastectomy radiotherapy with or without irradiation of the 
SNR, and to compare the acute and late adverse events 
associated with radiotherapy in both study arms. 
Between July 2007 and December 2012, women with 
mastectomy (minimum 6 removed nodes but not more than 9 
positive) and negative margins, who had received adjuvant 
chemotherapy, were centrally randomized to receive, as 
adjuvant, 40 Gy in 15 fractions to: the chest wall concurrent 
with 40 Gy in 15 fractions to the SNR; or chest wall (CW) 
irradiation alone. There was no attempt to irradiate the IMC. 
Recurrences were classified relative to the irradiation 
volumes as 'local' (in the CW fields), 'regional' (in the SNR 
location), and 'others'. 
Results: There were 469 women randomized, 237 to CW+SNR 
irradiation and 232 to CW only. The mean follow-up was 3.4 
years from mastectomy. By order of SNR and CW there no 
statistically significant differences for: 7 vs. 1 local failure; 8 
vs. 3 regional failures; and 37 vs. 33 distant failures. These 
events affected 75 patients (crude 16%). With 60 deaths 
(crude 12.8%) the overall survival by Kaplan-Meier was 84% at 
5-yr from mastectomy. This was not statistically different 
between trial arms (82% CW+SNR vs. 87% CW, p=0.17 by 
stratified analysis, further adjusted for stage and negative 
receptor status).  
In 283 patients with 1-3 positive axillary nodes, and with a 
3.4 years median follow-up, the overall survival was 
equivalent, and very similar results were also observed for 
the 57 cases with only upper-inner quadrant primaries, of 
whom 52 were node-positive in the axilla. There was no 
difference in the experience of toxicities including arm 
lymphedema. 
Conclusions: There was no difference in local, regional or 
distant failures or in toxicities across study arms. 
Hypofractionation was adopted by participating centres, thus 
sparing resources. Long term follow-up is needed for a 
definitive conclusion on the postoperative value of SNR 
irradiation in addition to effective systemic therapy. 
Although well tolerated, SNR irradiation did not show a 
clinical outcome benefit under the conditions of this 
randomized trial. 
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Purpose/Objective: Evidence is limited for locally advanced 
non-metastatic rectal cancer as to whether it is best 
managed with neo-adjuvant chemo-radiation (50 Gy/25 
fractions, A). Short-course radiotherapy (RT) (25 Gy/5 
fractions) would spare RT resources and it could be followed 
by two cycles of chemotherapy prior to surgery (B). This 
prospective, international, multi-center randomized trial of 
the IAEA compares A with B, surgery equally intended four 
months post-randomization. 
Materials and Methods: A total of 142 patients were accrued 
Apr 2011 to Jan 2014 (78 Mumbai, 15 Croatia, 15 Cape Town, 
12 Cuba, 11 Colombia, 7 Indonesia, 3 Coimbatore and 1 
Pretoria). A further 5 recently randomized cases are not yet 
evaluable. Radiation was 3-D planned, and for T4 cases 
included involved organs and anterior pelvic nodes. Primary 
outcomes were surgical resection and pathological margin 
status. At five months, patients were to receive a course of 
chemotherapy. Scheduled follow-up was every 3 months if 
with disease, or every 6 months if no evidence of disease. 
Relative safety of the two treatment regimens was 
determined from grades of adverse events (AE, CTCv4), 
stoma-related events and lab. tests. 
Results: Long-course (A) and short-course (B) arms had 71 
patients each with no statistical differences in patient and 
disease variables at baseline. Mean age was 50.7 yr and 93 
were male. Pathology on initial biopsy was 20 G1, 97 G2, and 
25 G3. Tumor location was 100 lower, 34 mid, and 8 upper 
rectums. Mean tumor length was 6.8 cm (range 2-20 cm) with 
a mean CEA of 25.9. Stage on initial imaging was 60 T4, 81 T3 
and 1 T2, plus 44 N2, 71 N1 and 37 N0. The CRM was deemed 
at-risk in 130 (82/82 non-T4 and 48/60 T4 cases). Fixity was 
in 52%, with 22% tethered and 26% mobile. Follow-up through 
Nov 2014, to a maximum 3.5 yr, gave a mean observation 
time of 1.54 yr for all 100 cases still alive. With 17 A and 25 B 
cases deceased, overall survival by Kaplan-Meier at 2.5 yr 
was 63% for A (95CI 47-76%) and 55% for B (95CI 39-68%); p = 
0.13 by Cox regression stratified by participating center and 
if T4. During neo-adjuvant treatment, CEA decline and down-
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staging occurred, but were not different by study arm. 
Surgical resection rate was 49/71 in A, and 43/71 in B, with 
total margin status of 83 R0, 6 R1 and 3 R2, which by study 
arm was A 45:2:2 and B 38:4:1, p=0.6. Grades of AE, stoma-
related events, non-stoma-related surgical complications, 
and lab work were similar.  
Conclusions: Differences in surgical resection rates (69% vs. 
60%), R0 pathological margins (62% vs. 52%), and overall 
survival (63% and 55%) were not statistically significant, while 
relative safety was demonstrated for short-course RT. With a 
mean follow-up of 1.5 years, the preliminary results of this 
trial do not show a significant difference between 
randomization arms. An operability rate of 60% is important 
for a group of patients deemed inoperable/borderline at 
diagnosis in this group of developing countries.  
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Purpose/Objective: Single dose radiotherapy is standard 
treatment for painful bone metastases but the optimal dose 
remains incertain. This multi-centre, international, 
randomised radiotherapy trial compared a single dose of 8 Gy 
(n = 325) with that of 4 Gy (n = 326) to relieve pain arising 
from a single bone metastasis. 
Materials and Methods: Patients aged ≥ 18 years with bone 
pain, a histological diagnosis of malignancy, radiological 
evidence of bone metastasis at the site of pain and a life 
expectancy of ≥ 12 weeks were eligible. Exclusion criteria 
were myeloma, bone metastasis in previously irradiated sites, 
previous radioisotope treatment, or complicated bone 
metastasis. 
Pain relief at baseline, 4, 8, 12, 24 and 52 weeks was 
assessed using a Categorical Scale (CS) and a Visual Analogue 
Scale (VAS). The primary endpoint was the difference in the 
proportion of responders at 4 weeks.  
Results: There were 325 patients randomized to the 8Gy arm 
and 326 to the 4Gy arm with no significant difference in the 
distribution of demographic features or other co-variates 
between dose groups. 
Table 1 shows crude incidence of pain relief (all follow-ups) 
and prevalence at 4 weeks for CR, PR, NR and OR. There was 
a significant difference between dose groups when a global 
comparison was made for all follow-up times.. At the other 
intervals (8 to 52 weeks) both CRs and ORR was higher after 8 
Gy (statistically significant only at 8 weeks got CR; p = 0.03 
and at 8 and 52 weeks (p = 0.03 for ORTable 1 also 
summarises pain relief using the VAS method. Overall 
incidence and 4-week prevalence of pain relief was 
significantly higher after 8 Gy. 
The Kaplan-Meier actuarial rate (categorical scale) at 4 
weeks showed no significant difference in CR. The ORR was 
80% after 8 Gy compared to 68% after 4 Gy (log rank p = 
0.0015). 
A total of 117 of re-treatments were given of which 72 were 
in the 4 Gy dose group and 45 in the 8 Gy arm (p = 0.01). 
Table 1. Incidence (all follow-ups) and prevalence at 4 weeks 
of response to pain for patients with complete (CR), partial 
(PR), no (NR) and overall response (OR) using the categorical 
(CS) and visual analogue (VAS) scales. 
 
 
 
Conclusions: In a wide range of healthcare settings single 
dose radiotherapy is highly effective at achieving pain relief. 
Overall 8Gy is associated with a higher probability of pain 
relief from metastatic bone pain than 4Gy but there was still 
a high likelihood of pain response after the lower dose of 4 
Gy [71% (CS) and 82% VAS] although a significantly higher 
retreatment rate after 4Gy.  
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